Subcutaneous implantable defibrillator: State-of-the art 2013

Table 2 Clinical subcutaneous implantable cardioverter-defibrillator case series n (%)

	Bardy et al[8] (2010)	Jarman et al[15] (2012)	Aydin et al[11] (2012)	Olde Nordkamp et al[14] (2012)	Köbe et al[12] (2013)	Jarman et al[16] (2013)	Burke et al[9] (ongoing, initial results)
Number of patients	55	16	40	118	69	111	304
Male	80%	56%	70%	75%	73%	N/A	74%
Age [median (range)/ mean ± SD]	56 ± 13	23 (10-48)	42 ± 15	50 ± 15	46 ± 16	33 (10-87)	52 ± 16
Primary prevention	78%	N/A	44%	60%	59%	50%	79%
Secondary prevention	22%	N/A	56%	40%	41%	50%	21%
Underlying pathology
Ischemic cardiomyopathy or idiopathic dilated cardiomyopathy	85%	0%	45%	57%	52%	19%	52%
Hypertrophic cardiomyopathy	N/A	0%	13%	N/A	15%	20%	9%
Congenital heart disease	4%	25%	3%	1%	4%	12%	N/A
Electrical heart disease1	N/A	75%	33%	26%	20%	43%	12%
Others	11%	0%	6%	16%	10%	7%	27%
Follow-up
Mean/median follow-up (mo)	10	9	8	18	7	13	N/A
Patients with re-interventions	6 (11)	3 (19)	5 (13)	16 (14)	3 (4)	19 (17)	92% procedure-related complication-free rate at 180 d
Patients with inappropriate shocks	5 (9)	4 (25)	2 (5)	15 (13)	3 (4)	17 (15)	38 (13)
Patients with appropriate shocks	3 (5)	4 (25)	4 (10)	8 (7)	3 (4)	13 (12)	16 (5)
Spontaneous VT/VF episode successfully converted by S-ICD or spontaneously converted	100%	100% [2 VF episodes with prolonged time (24 and 27 s) to therapy]	96% (1 episode of electrical storm was terminated by external shocks)	100%	100%	96% (1 death, see text for details)	100%

¹Brugada syndrome; long QT syndrome; catecholamine polymorphic ventricular tachycardia; idiopathic ventricular fibrillation. N/A: Data not available; S-ICD: Subcutaneous implantable cardioverter-defibrillator; VT: Ventricular tachycardia; VF: Ventricular fibrillation.